Longeveron Said ELPIS I Met Its Primary Endpoint Of Safety Through 1-year Post-treatment, With 100% Survival Rate
Portfolio Pulse from Benzinga Newsdesk
Longeveron Inc. announced positive long-term survival data from its ELPIS I Phase 1 clinical trial, showing 100% survival and no heart transplants needed after 5 years. This supports the potential of Lomecel-BTM as an adjunct therapy for HLHS. ELPIS II Phase 2b trial is ongoing.
October 27, 2024 | 8:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longeveron Inc. reported 100% survival and no heart transplants needed in its ELPIS I trial, indicating strong potential for its Lomecel-BTM therapy. This could positively impact LGVN's stock as it highlights the therapy's effectiveness.
The announcement of 100% survival and no heart transplants in the ELPIS I trial is a significant achievement for Longeveron, showcasing the potential of Lomecel-BTM. This positive data could boost investor confidence and positively impact LGVN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100